Teyi Pharmaceutical Group Co Ltd (002728) - Total Assets
Based on the latest financial reports, Teyi Pharmaceutical Group Co Ltd (002728) holds total assets worth CN¥2.33 Billion CNY (≈ $340.67 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Teyi Pharmaceutical Group Co Ltd (002728) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Teyi Pharmaceutical Group Co Ltd - Total Assets Trend (2009–2025)
This chart illustrates how Teyi Pharmaceutical Group Co Ltd's total assets have evolved over time, based on quarterly financial data. Check Teyi Pharmaceutical Group Co Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Teyi Pharmaceutical Group Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Teyi Pharmaceutical Group Co Ltd's total assets of CN¥2.33 Billion consist of 37.1% current assets and 62.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 5.5% |
| Accounts Receivable | CN¥260.17 Million | 11.3% |
| Inventory | CN¥237.63 Million | 10.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥148.77 Million | 6.4% |
| Goodwill | CN¥517.60 Million | 22.4% |
Asset Composition Trend (2009–2025)
This chart illustrates how Teyi Pharmaceutical Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Teyi Pharmaceutical Group Co Ltd worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Teyi Pharmaceutical Group Co Ltd's current assets represent 37.1% of total assets in 2025, a decrease from 68.9% in 2009.
- Cash Position: Cash and equivalents constituted 5.5% of total assets in 2025, down from 10.3% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 28.0% of total assets, an increase from 10.0% in 2009.
- Asset Diversification: The largest asset category is goodwill at 22.4% of total assets.
Teyi Pharmaceutical Group Co Ltd Competitors by Total Assets
Key competitors of Teyi Pharmaceutical Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Teyi Pharmaceutical Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.01 | 2.02 | 0.96 |
| Quick Ratio | 1.43 | 1.31 | 0.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥448.23 Million | CN¥393.21 Million | CN¥-24.45 Million |
Teyi Pharmaceutical Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between Teyi Pharmaceutical Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.27 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | -3.7% |
| Total Assets | CN¥2.31 Billion |
| Market Capitalization | $603.16 Million USD |
Valuation Analysis
Below Book Valuation: The market values Teyi Pharmaceutical Group Co Ltd's assets below their book value (0.26x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Teyi Pharmaceutical Group Co Ltd's assets decreased by 3.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Teyi Pharmaceutical Group Co Ltd (2009–2025)
The table below shows the annual total assets of Teyi Pharmaceutical Group Co Ltd from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.31 Billion ≈ $338.23 Million |
-3.73% |
| 2024-12-31 | CN¥2.40 Billion ≈ $351.32 Million |
-4.45% |
| 2023-12-31 | CN¥2.51 Billion ≈ $367.68 Million |
-1.30% |
| 2022-12-31 | CN¥2.55 Billion ≈ $372.50 Million |
+23.20% |
| 2021-12-31 | CN¥2.07 Billion ≈ $302.35 Million |
-8.42% |
| 2020-12-31 | CN¥2.26 Billion ≈ $330.14 Million |
-0.03% |
| 2019-12-31 | CN¥2.26 Billion ≈ $330.24 Million |
+9.15% |
| 2018-12-31 | CN¥2.07 Billion ≈ $302.55 Million |
+7.19% |
| 2017-12-31 | CN¥1.93 Billion ≈ $282.27 Million |
+20.32% |
| 2016-12-31 | CN¥1.60 Billion ≈ $234.60 Million |
+0.32% |
| 2015-12-31 | CN¥1.60 Billion ≈ $233.85 Million |
+93.57% |
| 2014-12-31 | CN¥825.60 Million ≈ $120.81 Million |
+82.03% |
| 2013-12-31 | CN¥453.54 Million ≈ $66.37 Million |
+16.83% |
| 2012-12-31 | CN¥388.22 Million ≈ $56.81 Million |
+37.08% |
| 2011-12-31 | CN¥283.21 Million ≈ $41.44 Million |
+12.06% |
| 2010-12-31 | CN¥252.73 Million ≈ $36.98 Million |
+33.26% |
| 2009-12-31 | CN¥189.65 Million ≈ $27.75 Million |
-- |
About Teyi Pharmaceutical Group Co Ltd
Teyi Pharmaceutical Group Co.,Ltd engages in the research and development, production, and sale of Chinese patented medicines, pharmaceutical preparations, raw materials, and products in the People's Republic of China. The company's products are used in respiratory system, cardiovascular and cerebrovascular, respiratory, cardiovascular, and digestive systems. The company was formerly known as Gua… Read more